Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.500
+0.020 (1.35%)
At close: Jun 26, 2026, 4:00 PM EDT
1.475
-0.025 (-1.65%)
After-hours: Jun 26, 2026, 5:21 PM EDT
Coherus Oncology Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coherus Oncology stock have an average target of 8.25, with a low estimate of 4.00 and a high estimate of 12. The average target predicts an increase of 450.00% from the current stock price of 1.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Coherus Oncology stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $10 | Buy | Reiterates | $10 | +566.67% | Jun 22, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 28, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $4 | Buy | Maintains | $4 | +166.67% | May 13, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $7 | Buy | Reiterates | $7 | +366.67% | May 12, 2026 |
| Guggenheim | Guggenheim | Buy Initiates $12 | Buy | Initiates | $12 | +700.00% | May 12, 2026 |
Financial Forecast
Revenue This Year
73.02M
from 42.17M
Increased by 73.15%
Revenue Next Year
100.07M
from 73.02M
Increased by 37.05%
EPS This Year
-0.75
from -1.36
EPS Next Year
-1.02
from -0.75
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 140.1M | 113.9M | |
| Avg | 73.0M | 100.1M | |
| Low | 57.7M | 78.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 232.2% | 55.9% | |
| Avg | 73.1% | 37.0% | |
| Low | 36.8% | 7.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.26 | -1.02 | |
| Avg | -0.75 | -1.02 | |
| Low | -1.23 | -1.02 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.